Evidence map›Paper›PMID 41177856›Full record

ArticleAllergy2026

Trajectory-Based Clustering to Identify Asthma Subgroups Responsive to the Selective CXCR2 Antagonist, AZD5069.

Khezia Asamoah, Freda Yang, Ian M Adcock, Dragana Vuckovic, Mohib Uddin, Kian Fan Chung, Marc Chadeau-Hyam

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Khezia AsamoahMRC Centre for Environment and Health & Department of Epidemiology and Biostatistics, Faculty of Medicine, School of Public Health, Imperial College London, London, UK.
Freda YangNational Heart and Lung Institute, Imperial College London, London, UK.
Ian M AdcockNational Heart and Lung Institute, Imperial College London, London, UK.ORCID https://orcid.org/0000-0003-2101-8843
Dragana VuckovicMRC Centre for Environment and Health & Department of Epidemiology and Biostatistics, Faculty of Medicine, School of Public Health, Imperial College London, London, UK.
Mohib UddinAstraZeneca, BioPharmaceuticals R&D, Gothenburg, Sweden.ORCID https://orcid.org/0000-0002-2412-2657
Kian Fan ChungNational Heart and Lung Institute, Imperial College London, London, UK.ORCID https://orcid.org/0000-0001-7101-1426
Marc Chadeau-HyamMRC Centre for Environment and Health & Department of Epidemiology and Biostatistics, Faculty of Medicine, School of Public Health, Imperial College London, London, UK.ORCID https://orcid.org/0000-0001-8341-5436

Funding

AstraZeneca NCT01704495
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

asthmaasthma treatmentbiomarkers

Identifiers

PMID41177856
PMCPMC12773661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.